Dr. Doug Devries details how OptiLight therapy is tailor-made for optometry and shares his advice for bringing the technology into an OD practice.
Fishman et al (2020): Real-Time Video Microscopy of In Vitro Demodex Death by Intense Pulsed Light
An in-vitro study demonstrated that, with settings used for treatment of dry eye due to meibomian gland dysfunction (MGD), Lumenis IPL with OPTTM destroyed an isolated Demodex mite.
Intense pulsed light therapy aims at underlying cause
Reviewing the science behind OptiLight, Dr. Art Epstein explains its effects on inflammation, meibomian gland structure and function, TBUT and more.
Choi et al (2019): Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines
In a prospective, single arm study, Lumenis IPL with OPT™ improved signs and symptoms of Dry Eye Disease due to MGD, and decreased tear levels of key inflammation markers. The decrease of two of these markers were correlated with improvement in meibum expressibility.
SLT is a cost-effective, first-line glaucoma approach
Dr. Nate Radcliffe shares how Lumenis SLT is a cost-effective first-line approach for patients with glaucoma in this video from ASCRS San Diego.
Arita et al. (2019): Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dsyfunction
The results of a prospective, random control trial show the combination of Lumenis IPL with OPT™ and Meibomian Gland Expression (MGX) improves tear film homeostasis and ameliorates ocular symptoms in patients with refractory Meibomian Gland Dysfunction (MGD).
BLOG: Prepare for dry eye flares to satisfy, retain patients
As a dry eye specialist in a multispecialty practice, Dr. Roberto “Bobby” Saenz offers advice on comprehensive therapy, including treatment for flares.
Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLight™
Lumenis Ltd., the world’s largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authorization for Lumenis’ newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD).
Fundamental Help for Patients: A 6-Month Look at Implementing Optima IPL
After just 6 months with Optima IPL, Carly Rose, OD is seeing incredible patient results, an increased demand in dry eye services, and a fast ROI on her investment.
Preview of the New Digital Duet/Trio, the First Digital SLT+YAG
Steven Dell, MD and Derek Cunningham, OD get a hands-on look at the improved digital capabilities of the newly released Digital Duet/Trio.